News
BVS
9.50
+2.26%
0.21
Weekly Report: what happened at BVS last week (0615-0619)?
Weekly Report · 2d ago
Bioventus management to meet with Barrington
TipRanks · 06/16 20:08
Bioventus Price Target Maintained With a $15.00/Share by Canaccord Genuity
Dow Jones · 06/16 15:57
Bioventus Is Maintained at Buy by Canaccord Genuity
Dow Jones · 06/16 15:57
Bioventus Buy Rating Reiterated on Strengthening Fundamentals and Growth Pillars; $15 Price Target Maintained
TipRanks · 06/16 11:55
Weekly Report: what happened at BVS last week (0608-0612)?
Weekly Report · 06/15 10:31
Weekly Report: what happened at BVS last week (0601-0605)?
Weekly Report · 06/08 10:26
Bioventus Shareholders Back Directors and Auditor at 2026 Meeting
TipRanks · 06/04 12:19
Bioventus holds annual shareholder meeting, elects directors
PUBT · 06/04 11:54
Bioventus CFO to join Goldman Sachs Global Healthcare Conference fireside chat
PUBT · 06/02 11:03
Transcript: Bioventus Q1 2026 Earnings Conference Call
Benzinga · 06/01 10:46
Weekly Report: what happened at BVS last week (0525-0529)?
Weekly Report · 06/01 10:31
Weekly Report: what happened at BVS last week (0518-0522)?
Weekly Report · 05/25 10:35
Analysts Offer Insights on Healthcare Companies: Bioventus (BVS) and Elanco Animal Health (ELAN)
TipRanks · 05/24 01:10
Analyst Reiterates Buy on Bioventus, Maintains $14 Price Target Despite CMS Reimbursement Headwinds
TipRanks · 05/22 13:25
Bioventus Is Maintained at Outperform by Barrington Research
Dow Jones · 05/22 12:56
Bioventus Price Target Maintained With a $14.00/Share by Barrington Research
Dow Jones · 05/22 12:56
Bioventus Affirms Outlook After FDA Device Reclassification
TipRanks · 05/21 23:14
Bioventus Says FDA Reclassifies Exogen Ultrasound Bone Healing System To Class II Device On April 16, 2026; CMS Updates Medicare Fee Schedule For Non-Invasive Bone Growth Stimulators Effective May 18, 2026; Does Not Expect Material Impact From Exogen Reimbursement Changes In FY26; Reiterates 2026 Financial Guidance - SEC Filing
Benzinga · 05/21 21:18
BIOVENTUS INC - REITERATES 2026 FINANCIAL GUIDANCE - SEC FILING
Reuters · 05/21 21:12
More
Webull provides a variety of real-time BVS stock news. You can receive the latest news about Bioventus Inc. through multiple platforms. This information may help you make smarter investment decisions.
About BVS
Bioventus Inc. is a medical device company. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. It offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.